Trial Profile
A Pilot Study to Explore Preliminary Safety, Tolerability and Efficacy of ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency in Patients With Pulmonary Hypertension and Iron Deficiency Anemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ferric maltol (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms ORION-PH-1
- 17 Apr 2020 Status changed from completed to discontinued.
- 04 Apr 2020 Status changed from recruiting to completed.
- 17 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.